Novo Nordisk stock surged Thursday after its oral version of Wegovy helped patients lose a "significant" amount of weight.
Novo Nordisk (NVO) stock surged Thursday after its oral version of Wegovy helped patients lose a "significant" amount of weight over the course of 64 weeks.
Patients lost on average of 16.6% of their body weight while taking oral semaglutide, the act... [4416 chars]